Sugi Predict

Sugi Predict / Targets / MAP2K4

MAP2K4

Dual specificity mitogen-activated protein kinase kinase 4 · P45985 · MAP2K4 on Sugi Atlas →

23,781 patent compounds predicted against MAP2K4, 14,873 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL298332 SCHEMBL298332 0.56 14/20
SCHEMBL12222 SCHEMBL12222 0.57 9/20
SCHEMBL443588 SCHEMBL443588 0.48 9/20
SCHEMBL298159 SCHEMBL298159 0.56 7/20
SCHEMBL441029 SCHEMBL441029 0.48 7/20
SCHEMBL220002 SCHEMBL220002 0.58 6/20
SCHEMBL599945 SCHEMBL599945 0.43 6/20
SCHEMBL144764 SCHEMBL144764 0.65 5/20
SCHEMBL12136 SCHEMBL12136 0.50 5/20
SCHEMBL141237 SCHEMBL141237 0.49 5/20
SCHEMBL628641 SCHEMBL628641 0.52 4/20
SCHEMBL117222 SCHEMBL117222 0.51 4/20
SCHEMBL176805 SCHEMBL176805 0.45 4/20
SCHEMBL12247 SCHEMBL12247 0.43 4/20
SCHEMBL144396 SCHEMBL144396 0.68 3/20
SCHEMBL413368 SCHEMBL413368 0.53 3/20
SCHEMBL628596 SCHEMBL628596 0.52 3/20
SCHEMBL381384 SCHEMBL381384 0.50 3/20
SCHEMBL300191 SCHEMBL300191 0.48 3/20
SCHEMBL142647 SCHEMBL142647 0.47 3/20

Clinical trials — most relevant to MAP2K4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor PHASE2COMPLETED
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma PHASE2COMPLETED
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma PHASE1COMPLETED
Phase I Trial of VS-6766 Alone and in Combination With Everolimus PHASE1COMPLETED
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP2K4 binder may also engage these)

ProteinNameSimilarity
P47809 — 1.000 P47809 →
Q07192 — 0.993 Q07192 →
Q90321 — 0.993 Q90321 →
Q9DGE0 — 0.992 Q9DGE0 →
P31938 — 0.991 P31938 →
Q4KSH7 — 0.991 Q4KSH7 →
MAP2K7 Dual specificity mitogen-activated protein kinase kinase 7 0.990 landscape →
Q90891 — 0.990 Q90891 →
Q91447 — 0.990 Q91447 →
MAP2K3 Dual specificity mitogen-activated protein kinase kinase 3 0.989 landscape →
Q63980 — 0.989 Q63980 →
Q9XT09 — 0.988 Q9XT09 →
Q1HG70 — 0.988 Q1HG70 →
O09110 — 0.988 O09110 →
Q05116 — 0.988 Q05116 →
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 0.987 landscape →
P36506 — 0.987 P36506 →
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 0.987 landscape →
P29678 — 0.987 P29678 →
Q24324 — 0.986 Q24324 →
Q20347 — 0.985 Q20347 →
Q01986 — 0.985 Q01986 →
Q99078 — 0.985 Q99078 →
Q9WVS7 — 0.984 Q9WVS7 →
Q62862 — 0.983 Q62862 →
Q10664 — 0.982 Q10664 →
Q5E9X2 — 0.981 Q5E9X2 →
MAP2K5 Dual specificity mitogen-activated protein kinase kinase 5 0.981 landscape →
A4K2M3 — 0.981 A4K2M3 →
P70236 — 0.981 P70236 →